Dr. Eric Topol’s longevity work identified daily habits to follow in a study of “super agers” who are healthy at ages 85 and above."I am taking my own advice," says Dr. Eric Topol, a 70-year-old cardiologist.He shares the tips that he follows: 🔗 https://t.co/5Z85p0DnBK https://t.co/imesX1s3rV ...

Industry Trend - More female scientists, entrepreneurs and influencers are entering the longevity space [1] Research Focus - Study of hormones and ovaries could unlock the key to a longer life for everyone [1]

More female scientists, entrepreneurs and influencers are entering the longevity space. Their study of hormones and ovaries could unlock the key to a longer life for everyone. https://t.co/oV4HbaJ1HU ...

Dr. Eric Topol’s longevity work identified daily habits to follow in a study of “super agers” who are healthy at ages 85 and above."I am taking my own advice," says Dr. Eric Topol, a 70-year-old cardiologist.He shares the tips that he follows: 🔗 https://t.co/AsUqRbjyBY https://t.co/ZxtaemuuWw ...

Both rapamycin and metformin have drawn the attention of the “live for ever” brigade. But what does the science say about their effectiveness? https://t.co/FfnxuNij4GIllustration: Cristina Spanò https://t.co/pE6psv9Mbi ...

Core Insights - Jupiter Neurosciences, Inc. is launching Nugevia™ GLO, a supplement targeting the "beauty-from-within" market, focusing on skin health through clinically validated cellular science [1][2] - The product utilizes JOTROL™, a proprietary resveratrol delivery technology, and NovaSOL® Astaxanthin, enhancing skin vitality at the cellular level [2][3] - GLO is positioned as a premium supplement, appealing to a demographic of women over 35 seeking scientifically grounded skin and aging solutions [4] Product Details - Nugevia GLO is designed to support skin health by promoting cellular defense, collagen integrity, and hydration [1][4] - The supplement regimen consists of two capsules per day for optimal absorption and compliance [5] - Key benefits include enhanced collagen synthesis, improved hydration, reduced pigmentation, and protection against oxidative stress [7] Market Strategy - The launch of GLO represents a strategic shift for Jupiter into the consumer wellness sector, aiming to create a high-margin revenue stream [4] - The company anticipates significant top-line growth from the Nugevia product line, which will support clinical development and enhance long-term shareholder value [5] - Jupiter is targeting the $8 trillion longevity market, leveraging its proprietary science to reach a broader audience [2] Scientific Validation - JOTROL™ has shown a nine-fold increase in resveratrol bioavailability in Phase I trials, addressing previous issues with resveratrol's effectiveness [3][9] - The combination of JOTROL™ and Astaxanthin is expected to create a leading solution for skin health and systemic rejuvenation [3][10] - Jupiter's therapeutic pipeline includes ongoing clinical programs for CNS disorders, with JOTROL™ serving as a foundation for both therapeutic and consumer products [6][10]

Core Viewpoint - Minovia Therapeutics is advancing its mitochondrial augmentation technology (MAT) to address mitochondrial diseases and age-related decline, with its lead program MNV-201 receiving FDA Fast Track and Rare Pediatric Disease designations, and is preparing for its first pivotal clinical trial [1][3][6] Company Overview - Minovia Therapeutics is a clinical-stage biotechnology company based in Haifa, Israel, focused on developing therapies to treat mitochondrial diseases and combat aging [1][4][14] - The company is entering a business combination with Launch One Acquisition Corp, which will create a publicly traded entity named Mito US One Ltd, expected to be listed on Nasdaq [1][6][11] Technology and Product Development - Minovia's MAT platform aims to restore energy production in cells by enriching them with healthy mitochondria, potentially addressing a wide range of diseases including neurodegenerative and metabolic disorders [4][5] - The lead product, MNV-201, is currently in a Phase 2 trial for Pearson Syndrome and a Phase 1b study for low-risk Myelodysplastic Syndrome (MDS) [6][14] - The company has treated 23 patients with various mitochondrial conditions, showing significant improvements in health outcomes without adverse effects [5][6] Financial Aspects and Transaction Details - The business combination values Minovia at a pre-money equity valuation of $180 million, with additional financing expected to support its growth and development pipeline [10] - Launch One's trust account currently holds approximately $239.7 million in cash, which may be partially available to the combined company after the transaction [6][10] Market Potential - Minovia aims to become a leader in the $1+ trillion longevity and regenerative medicine market, with plans to launch MAT-based offerings through global partnerships starting in 2026 [8][9] - The company believes its accumulated clinical data and preclinical results position it well to capitalize on the growing demand for mitochondrial regenerative medicine [8][9]

Core Insights - Klotho Neuroscience, Inc. is partnering with leading researchers from the Okinawa Research Center for Longevity Science to explore the role of the Klotho gene in promoting longevity and reducing neurodegenerative diseases [1][2][3] Company Overview - Klotho Neuroscience, Inc. (NASDAQ: KLTO) focuses on developing cell and gene therapies targeting neurological conditions such as ALS, Alzheimer's Disease, and Parkinson's Disease [1][4] - The company utilizes a patented form of the Klotho gene, specifically the secreted alpha-Klotho protein isoform (s-KL), in its innovative therapies [4] Research and Development - Preliminary data from ORCLS suggests that the alpha-Klotho gene and its protein isoform may contribute to healthy longevity, with decreased levels correlating with various age-related diseases [2][3] - The partnership will analyze blood samples from centenarians to assess the Klotho protein's role in longevity and its potential protective effects against neurodegenerative disorders [3][4] Historical Context - Okinawa is recognized as the original Blue Zone, known for its high concentration of centenarians, validated by extensive research from ORCLS over the past five decades [2][3] - ORCLS has a history of significant discoveries in human aging, including the identification of longevity genes and their translation from model organisms to humans [3]

Investor Day & Longevity Summit June 12, 2025 abacusgm.com Disclaimer General. This presentation (this "Presentation") is provided solely for informational purposes. This Presentation is subject to update, completion, revision, verification and further amendment without notice. None of Abacus Global Management, Inc. (the "Company", "Abacus", Abacus Global Management", "we", "our", or "us") or its affiliates has authorized anyone to provide interested parties with additional or different information. The inf ...

Many Americans expect a long retirement but underestimate how long they’ll live. Learn why longevity literacy is essential to building a secure plan. https://t.co/p7RUpB9jNu ...